Spinoff Biohaven launches with $258M and “incredible pipeline”
Biohaven Ltd. launched today as a new publicly traded company focused on delivering innovative life-changing…
October 4, 2022 - 4 minutes
Neurological disorders
NeuShen Therapeutics closes $20M pre-A financing
Chinese biotech company NeuShen Therapeutics, Inc. has closed an approximately $20 million series pre-A financing…
September 29, 2022 - 3 minutes
Research identifies new treatment target for CNS injury and neurological disease
Researchers in Birmingham in the U.K. have identified a potential target for drugs to treat…
September 22, 2022 - 3 minutes
Emyria starts program with neuroscience drug discovery CRO
Emyria Limited, a clinical stage biotech, is set to work with PsychoGenics, a specialist neuroscience…
September 22, 2022 - 2 minutes
NodThera reveals positive results for inflammasome inhibitors
Biotech company NodThera has announced positive phase 1 clinical readouts for its first and second…
September 21, 2022 - 2 minutes
FDA clears Cellenkos ALS drug for trial
Cellenkos, Inc., a clinical stage biotech company, has announced that the U.S. Food and Drug…
September 21, 2022 - 3 minutes
Collaboration to explore gene therapy products for neurodegenerative disorders
Coave Therapeutics is collaborating with the Institute of Neurodegenerative Diseases (IMN) of Bordeaux to develop…
September 14, 2022 - 3 minutes
First patient enrolled in phase 3 study of drug for Charcot-Marie-Tooth disease
The first patient has been enrolled in a phase 3 study of a treatment for…
September 12, 2022 - 3 minutes
Ionis presents positive study results at International Symposium on amyloidosis
Ionis Pharmaceuticals, Inc. has presented positive results from a planned 35-week interim analysis of the…
September 7, 2022 - 4 minutes
Scientists unravel mystery behind neurodegenerative disease protein
Scientists have unraveled the mystery behind the mechanism behind a type of protein that leads…
August 30, 2022 - 4 minutes
Gate Neurosciences emerges from stealth to tackle CNS diseases
Gate Neurosciences has officially launched to develop its next-generation therapeutics addressing synaptic dysfunction in patients…
August 23, 2022 - 3 minutes
Sosei Heptares and AbbVie enter second collaboration targeting neurological diseases
A new drug discovery collaboration has taken place between Japanese Sosei Group Corporation and UK-based…
August 2, 2022 - 2 minutes
